北美、欧洲和亚太女性性健康市场 – 行业趋势和 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

北美、欧洲和亚太女性性健康市场 – 行业趋势和 2030 年预测

  • Healthcare
  • Published Report
  • Jul 2023
  • Country Level
  • 350 页面
  • 桌子數: 235
  • 图号: 101

北美、欧洲和亚太女性性健康市场,按检测类型(沙眼衣原体和淋病奈瑟菌 (CT/NG) 检测、HCV 检测、HIV 检测、宫颈癌、结核病、细菌性阴道病、人乳头瘤病毒 (HPV) 检测、生殖器疱疹、移植病毒并发症等)、检测地点(非处方检测、自我采集/在家检测、即时诊断检测等)、技术(分子、血清学、培养/生物分离等)、最终用户(医院、诊所、诊断中心、实验室、家庭护理环境等)、分销渠道(线上和线下)划分 - 行业趋势和预测到 2030 年。

北美、欧洲和亚太地区女性性健康市场分析与洞察

人们对女性性健康的认识不断提高,增强了市场需求。为获得更好的医疗服务而增加的医疗支出也促进了市场的增长。在这一关键时期,主要的市场参与者专注于各种服务的推出和批准。此外,工艺和技术的改进也促进了女性性健康需求的增加。

北美、欧洲和亚太女性性健康市场北美、欧洲和亚太女性性健康市场

由于市场参与者的增加和先进服务的可用性,预计市场将在预测年增长。与此同时,制造商正致力于开发推出新服务和高效准确的性健康测试的活动。先进医疗技术的不断发展进一步推动了市场的增长。然而,生产和商业化女性性健康产品的严格规定等困难预计将抑制市场的增长。

预计医疗保健支出的增加将为市场带来机遇。然而,高昂的检测成本可能会对市场增长构成挑战。

各公司正在采取举措,逐步推动市场增长:

例如,

  • 2023 年 2 月,全球领先的医疗技术公司 BD 宣布美国食品药品监督管理局 (FDA) 批准 BD Onclarity HPV 检测试剂与 ThinPrep Pap 检测试剂一起使用。此项批准将有助于该公司改进产品并研发新产品
  • 2020 年 9 月,罗氏公司宣布在美国推出 Elecsys HIV Duo 免疫测定法,该检测法于 2020 年 4 月获得 FDA 批准。通过分别测量 HIV p24 抗原(病毒)和抗 HIV 抗体(由免疫反应引起),该检测法可以检测出急性HIV感染。该产品的推出帮助该公司扩大了产品组合

Data Bridge Market Research 分析称,北美女性性健康市场预计到 2030 年将达到 28.3439 亿美元的价值,预测期内的复合年增长率为 9.5%。

Data Bridge Market Research 分析称,到 2030 年,欧洲女性性健康市场预计将达到 14.8416 亿美元的价值,预测期内的复合年增长率为 8.7%。

Data Bridge Market Research 分析称,到 2030 年,亚太女性性健康市场预计将达到 12.7782 亿美元的价值,预测期内的复合年增长率为 10.3%。

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021 (可定制至 2015-2020)

定量单位

收入(百万美元),定价(美元)

涵盖的领域

检测类型(沙眼衣原体和淋病奈瑟菌 (CT/NG) 检测、HCV 检测、HIV 检测、宫颈癌、结核病、细菌性阴道病、人乳头瘤病毒 (HPV) 检测、生殖器疱疹、移植病毒并发症等)、检测地点(非处方检测、自我采集/在家检测、即时检测等)、技术(分子、血清学、生物体培养/分离等)、最终用户(医院、诊所、诊断中心、实验室、家庭护理环境等)、分销渠道(线上和线下)

覆盖国家

美国、加拿大、德国、法国、英国、中国、日本和澳大利亚

涵盖的市场参与者

Trinity Biotech、BIOMÉRIEUX、Accuquik Test Kits.、JOYSBIO(天津)生物科技有限公司、Arbor Vita、Randox Laboratories Ltd.、Chembio Diagnostics, Inc.、Cepheid.、ELITech Group、Abbott、F. Hoffmann-La Roche Ltd.、Bio-Rad Laboratories, Inc.、Sekisui Diagnostics(SEKISUI Chemical Co. Ltd. 的一部分)、Quidel Corporation、BD.、OraSure Technologies、Hologic, Inc.、Biomed Diagnostics 以及 DCN DX Brand 等。

北美、欧洲和亚太女性性健康市场定义

女性性健康是指与女性性健康相关的整体幸福感和满意度。影响女性的性病包括各种疾病,例如性传播感染 (STI),例如衣原体、淋病、疱疹、人乳头瘤病毒 (HPV) 和梅毒,以及其他疾病,例如阴道感染、尿路感染 (UTI)、盆腔炎 (PID)和荷尔蒙失调。女性性健康市场涵盖一系列诊断工具和方法,包括实验室测试、分子诊断、即时检测、成像技术和专门的医疗设备。

北美、欧洲和亚太地区女性性健康市场动态

本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容:    

驱动程序

  • 性传播疾病发病率不断上升

性传播感染 (STD) 是一个严重的全球公共卫生问题,在不同地区越来越普遍。性传播感染的增加对女性性健康市场产生了重大影响。它极大地影响了创造和扩大商品和服务以增强性健康和幸福感。不孕症、宫颈癌和艾滋病毒易感性增加只是性传播感染的长期影响及其带来的直接健康危害中的一小部分。促进全球女性的性福祉需要解决性传播感染率上升的问题。

以下是北美、欧洲和亚太地区性病患病率上升的几个案例和例子,以阐明其如何影响女性性健康市场。

克制

  • 耻辱和社会禁忌是一个挑战

在北美、欧洲和亚太地区,女性的性健康受到污名化并被视为社会禁忌,这是一个严重的问题。由于这些社会态度和信念,女性在尝试获取和寻求性健康服务和产品时会遇到障碍。

在北美,社会对性问题的偏见和禁忌可能会使女性难以公开谈论或讨论性健康问题。这种偏见可能源于社会或宗教期望,这可能导致女性产生内疚感和担心被评判。这种态度可能会阻碍女性寻求与性健康相关的信息、教育和医疗保健服务。

在欧洲,禁忌和社会羞耻感可能会阻碍人们公开谈论性健康问题并获得支持。文化、宗教和保守势力可能会使女性性健康问题长期存在污名。由于这种污名,女性可能不太可能寻求性健康治疗,也更难以对自己的身体和性需求做出明智的选择。

在亚太地区,根深蒂固的文化和社会标准经常导致女性性健康受到污名化和禁忌。男权社会结构、保守观点和获得全面性教育的机会有限,都助长了污名化的持续存在。女性可能会因为担心社会污名化、父母或社区的反对和评判而犹豫不决,不愿寻求性健康教育、检测和护理。

北美、欧洲和亚太女性性健康市场

机会

  • 增加性健康产品的批准和产品发布

越来越多的产品获批和上市为女性性健康市场的增长提供了重要机会。获批产品的可用性增强了消费者信心,确保了产品的安全性、有效性和质量。它还扩大了治疗选择,为性功能障碍等疾病提供了创新的解决方案。随着这些获批产品的可及性和可用性的提高,市场可以覆盖更广泛的消费者群体并满足以前未满足的需求。此外,新产品的获批和上市刺激了研究和创新,突破了技术的界限并推动了市场扩张。

挑战

  • 缺乏标准化、指导方针和道德考量

女性性健康市场面临的一个关键问题是缺乏标准化和道德考量。缺乏强有力的指导方针和法规给消费者和行业带来了重大挑战。主要问题之一是市场上产品质量参差不齐。此外,缺乏标准化测试协议阻碍了对这些产品的科学验证,导致基于证据的知识有限,阻碍了明智的决策。

产品质量不稳定:由于缺乏标准化规定,市场上女性性保健产品的质量参差不齐。这种缺乏一致性可能会危及消费者的安全和满意度,并可能导致不良健康影响或无效结果。

最新动态

  • 2023 年 3 月,Trinity Biotech plc 对肯尼亚卫生部宣布采用新的 HIV 快速检测算法表示欢迎。该新算法确立了 Trinity Biotech 的 TrinScreen HIV 作为筛查测试(A1 = 世界卫生组织 (WHO) 指南下的筛查测试)
  • 2022 年 5 月,Quidel Corporation(“QuidelOrtho”)宣布完成 Quidel Corporation(“Quidel”)与 Ortho Clinical Diagnostics Holdings plc(“Ortho”)合并交易,成立领先的体外诊断公司 QuidelOrtho。新公司总部位于加利福尼亚州圣地亚哥。此次合并还将有助于该公司扩大其在临床诊断领域的业务。

北美、欧洲和亚太女性性健康市场范围

北美、欧洲和亚太地区女性性健康市场分为五个显著的细分市场,例如测试类型、测试地点、技术、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略,并确定您的核心应用领域和目标市场的差异。  

北美、欧洲和亚太地区女性性健康市场(按测试类型划分)

  • 沙眼衣原体和淋病奈瑟菌 (CT/NG) 检测
  • 丙型肝炎病毒检测
  • 艾滋病毒检测
  • 宫颈癌
  • 结核
  • 细菌性阴道病
  • 人乳头瘤病毒 (HPV) 检测
  • 生殖器疱疹
  • 移植病毒并发症
  • 其他的

根据测试类型,市场细分为沙眼衣原体和淋病奈瑟菌 (CT/NG) 测试、HCV 测试、HIV 测试、宫颈癌、结核病、细菌性阴道病、人乳头瘤病毒 (HPV) 测试、生殖器疱疹、移植病毒并发症等。

北美、欧洲和亚太地区女性性健康市场(按测试地点划分)

  • 非处方测试
  • 自行收集/在家检测
  • 即时检测
  • 其他的

根据测试地点,市场分为非处方测试、自我采集/在家测试、即时检测等。

北美、欧洲和亚太地区女性性健康市场(按技术划分)

  • 分子
  • 血清学
  • 生物体的培养/分离
  • 其他的

根据技术,市场分为分子、血清学、生物体培养/分离等。

北美、欧洲和亚太地区女性性健康市场(按最终用户划分)

  • 医院
  • 诊所
  • 诊断中心
  • 实验室
  • 家庭护理环境
  • 其他的

根据最终用户,市场分为医院、诊所、诊断中心、实验室、家庭护理环境和其他。

北美、欧洲和亚太地区女性性健康市场(按分销渠道划分)

  • 在线的
  • 离线

根据分销渠道,市场分为线上和线下。

北美、欧洲和亚太女性性健康市场

北美、欧洲和亚太女性性健康市场区域分析/洞察

市场分为五个显著的部分:测试类型、测试地点、技术、最终用户和分销渠道。

本市场报告涵盖的国家包括美国、加拿大、德国、法国、英国、中国、日本和澳大利亚。

由于该地区艾滋病毒和丙型肝炎等性相关疾病的发病率很高,预计美国将主导北美市场。由于医疗支出增加,预计德国将主导欧洲市场。由于性健康意识的提高,预计中国将主导亚太市场。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在对国家数据进行预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战,以及销售渠道的影响。

竞争格局和北美、欧洲和亚太女性性健康市场份额分析

北美、欧洲和亚太女性性健康市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用优势、产品类型生命线曲线。以上提供的数据点仅与公司对北美、欧洲和亚太女性性健康市场的关注有关。

该市场的一些主要市场参与者包括 Trinity Biotech、BIOMÉRIEUX、Accuquik Test Kits.、JOYSBIO(天津)生物科技有限公司、Arbor Vita、Randox Laboratories Ltd.、Chembio Diagnostics, Inc.、Cepheid.、ELITech Group、Abbott、F. Hoffmann-La Roche Ltd.、Bio-Rad Laboratories, Inc.、Sekisui Diagnostics(SEKISUI Chemical Co. Ltd. 的一部分)、Quidel Corporation、BD.、OraSure Technologies、Hologic, Inc.、Biomed Diagnostics 和 DCN DX Brand 等。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TEST TYPE LIFELINE CURVE (NORTH AMERCA)

2.8 TEST TYPE LIFELINE CURVE (EUROPE)

2.9 TEST TYPE LIFELINE CURVE (ASIA-PACIFIC)

2.1 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.11 DBMR MARKET POSITION GRID

2.12 MARKET TESTING TYPE COVERAGE GRID

2.13 VENDOR SHARE ANALYSIS

2.14 SECONDARY SOURCES

2.15 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES MODEL

4.3 KEY STRATEGIC INITIATIVES

4.4 TREND ANALYSIS

4.4.1 TV (TRICHOMONAS VAGINALIS)

4.4.2 M. GEN (MYCOPLASMA GENITALIUM)

4.4.3 HIV

4.4.4 HBV, HCV (HEPATITIS B & C)

4.4.5 CMV (CYTOMEGALOVIRUS)

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES

5.1.2 GROWING AWARENESS ABOUT STDS

5.1.3 RISE IN THE PREFERENCE FOR HOME CARE TESTING IN WOMEN SEXUAL WELLNESS

5.2 RESTRAINTS

5.2.1 HIGH COST ASSOCIATED WITH TESTING

5.2.2 STIGMA AND SOCIAL TABOOS A CHALLENGE

5.3 OPPORTUNITIES

5.3.1 INCREASING PRODUCT APPROVALS AND PRODUCT LAUNCHES FOR SEXUAL WELLNESS

5.3.2 THE INCREASING PRODUCTS APPROVALS AND THEIR LAUNCHES

5.4 CHALLENGES

5.4.1 LACK OF STANDARDIZATION, GUIDELINES, AND ETHICAL CONSIDERATIONS

5.4.2 LACK OF COMPREHENSIVE EDUCATION

6 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE

6.1 OVERVIEW

6.2 HUMAN PAPILLOMAVIRUS (HPV) TESTING

6.3 GENITAL HERPES

6.4 CERVICAL CANCER

6.4.1 PAP SMEAR TEST

6.4.2 OTHER DIAGNOSTIC TESTS

6.5 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST

6.5.1 RAPID TEST KITS

6.5.2 SEROLOGY TESTS

6.5.3 DIRECT FLUORESCENT ANTIBODY TEST

6.5.4 OTHER TEST TYPES

6.6 HIV TEST

6.6.1 ANTIBODY TEST

6.6.2 NUCLEIC ACID TESTS (NATS)

6.6.3 OTHERS

6.7 HCV TEST

6.7.1 HCV ANTIBODY TESTING

6.7.2 HCV VIRAL LOAD TESTING

6.7.3 HCV GENOTYPING TESTING

6.7.4 BACTERIAL VAGINOSIS

6.8 TUBERCULOSIS

6.8.1 CULTURE BASED DIAGNOSIS

6.8.2 SPUTUM SPEAR MICROSCOPY

6.8.3 RAPID MOLECULAR DIAGNOSTICS

6.9 VIRAL COMPLICATIONS WITH TRANSPLANT

6.1 OTHERS

7 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION

7.1 OVERVIEW

7.2 POINT-OF-CARE TESTING

7.2.1 HUMAN PAPILLOMAVIRUS (HPV) TESTING

7.2.2 GENITAL HERPES

7.2.3 CERVICAL CANCER

7.2.4 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST

7.2.5 HIV TEST

7.2.6 HCV TEST

7.2.7 BACTERIAL VAGINOSIS

7.2.8 TUBERCULOSIS

7.2.9 VIRAL COMPLICATIONS WITH TRANSPLANT

7.2.10 OTHERS

7.3 SELF-COLLECTION/AT HOME TESTING

7.3.1 GENITAL HERPES

7.3.2 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST

7.3.3 HUMAN PAPILLOMAVIRUS (HPV) TESTING

7.3.4 HIV TEST

7.3.5 HCV TEST

7.3.6 BACTERIAL VAGINOSIS

7.3.7 CERVICAL CANCER

7.3.8 TUBERCULOSIS

7.3.9 VIRAL COMPLICATIONS WITH TRANSPLANT

7.3.10 OTHERS

7.4 OVER-THE-COUNTER TESTING

7.4.1 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST

7.4.2 HCV TEST

7.4.3 GENITAL HERPES

7.4.4 HUMAN PAPILLOMAVIRUS (HPV) TESTING

7.4.5 HIV TEST

7.4.6 BACTERIAL VAGINOSIS

7.4.7 CERVICAL CANCER

7.4.8 TUBERCULOSIS

7.4.9 VIRAL COMPLICATIONS WITH TRANSPLANT

7.4.10 OTHERS

7.5 OTHERS

8 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY

8.1 OVERVIEW

8.2 SEROLOGY

8.3 MOLECULAR

8.4 CULTURE/ISOLATION OF ORGANISM

8.5 OTHERS

9 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 PUBLIC

9.4 PRIVATE

9.5 CLINICS

9.5.1 WOMEN HEALTHCARE CLINICS

9.5.2 GYNECOLOGY CLINICS

9.5.3 OTHERS

9.6 DIAGNOSTIC CENTERS

9.7 LABORATORIES

9.8 HOME CARE SETTING

9.9 OTHERS

10 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 OFFLINE

10.3 ONLINE

11 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET : BY REGION

11.1 NORTH AMERICA

11.1.1 U.S.

11.1.2 CANADA.

11.2 EUROPE

11.2.1 GERMANY

11.2.2 U.K.

11.2.3 FRANCE

11.3 ASIA-PACIFIC

11.3.1 HINA

11.3.2 JAPAN

11.3.3 AUSTRALIA

12 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

12.2 COMPANY SHARE ANALYSIS: EUROPE

12.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13 SWOT ANALYSIS

14 NORTH AMERICA, EUROPE, ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET

14.1 HOLOGIC, INC.

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 PRODUCT PORTFOLIO

14.1.4 RECENT DEVELOPMENT

14.2 CEPHEID. (SUBSIDARY OF DANAHER)

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 PRODUCT PORTFOLIO

14.2.4 RECENT DEVELOPMENT

14.3 F. HOFFMANN-LA ROCHE LTD.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 PRODUCT PORTFOLIO

14.3.4 RECENT DEVELOPMENT

14.4 ABBOTT

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 PRODUCT PORTFOLIO

14.4.4 RECENT DEVELOPMENT

14.5 BIO-RAD LABORATORIES, INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 PRODUCT PORTFOLIO

14.5.4 RECENT DEVELOPMENT

14.6 ACCUQUIK TEST KITS. (ADVACARE PHARMA USA)

14.6.1 COMPANY SNAPSHOT

14.6.2 PRODUCT PORTFOLIO

14.6.3 RECENT DEVELOPMENT

14.7 ARBOR VITA CORPORATION

14.7.1 COMPANY SNAPSHOT

14.7.2 PRODUCT PORTFOLIO

14.7.3 RECENT DEVELOPMENT

14.8 BD.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.9 BIOMED DIAGNOSTICS, A DCN DX BRAND

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 BIOMÉRIEUX (2022)

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENT

14.11 CHEMBIO DIAGNOSTICS, INC. (2022)

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 ELITECH GROUP

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENT

14.13 JOYSBIO (TIANJIN) BIOTECHNOLOGY CO., LTD

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 ORASURE TECHNOLOGIES

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENT

14.15 QUIDEL CORPORATION

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENT

14.16 RANDOX LABORATORIES LTD.

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENT

14.17 SEKISUI DIAGNOSTICS (A PART OF SEKISUI CHEMICAL CO. LTD.)

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENT

14.18 TRINITY BIOTECH (2022)

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

表格列表

TABLE 1 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 2 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 3 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 4 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 5 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 6 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 7 NORTH AMERICA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 8 EUROPE CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 ASIA-PACIFIC CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 11 EUROPE CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 12 ASIA-PACIFIC CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 14 EUROPE HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 15 ASIA-PACIFIC HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 17 EUROPE HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 18 ASIA-PACIFIC HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 20 EUROPE TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 21 ASIA-PACIFIC TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 23 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 24 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 26 EUROPE POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 27 ASIA-PACIFIC POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 29 EUROPE SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 30 ASIA-PACIFIC SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 32 EUROPE OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 33 ASIA-PACIFIC OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 35 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 36 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 38 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 41 EUROPE HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 42 ASIA-PACIFIC HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 43 NORTH AMERICA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 44 EUROPE CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 45 ASIA-PACIFIC CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 46 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 47 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 48 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 49 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 50 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 51 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 52 NORTH AMERICA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 53 NORTH AMERICA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 54 NORTH AMERICA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 55 NORTH AMERICA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 56 NORTH AMERICA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 57 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 58 NORTH AMERICA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 59 NORTH AMERICA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 60 NORTH AMERICA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 61 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 62 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 63 NORTH AMERICA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 64 NORTH AMERICA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 65 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 66 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 67 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 68 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 69 U.S. CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 70 U.S. CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 71 U.S. HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 72 U.S. HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 73 U.S. TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 74 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 75 U.S. POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 76 U.S. SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 77 U.S. OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 78 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 79 U.S. WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 80 U.S. HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 81 U.S. CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 82 U.S. WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 83 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 84 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 85 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 86 CANADA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 87 CANADA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 88 CANADA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 89 CANADA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 90 CANADA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 91 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 92 CANADA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 93 CANADA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 94 CANADA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 95 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 96 CANADA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 97 CANADA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 98 CANADA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 99 CANADA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 100 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 101 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 102 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 103 EUROPE CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 104 EUROPE CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 105 EUROPE HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 106 EUROPE HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 107 EUROPE TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 108 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 109 EUROPE POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 110 EUROPE SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 111 EUROPE OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 112 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 113 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 114 EUROPE HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 115 EUROPE CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 116 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 117 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 118 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 119 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 120 GERMANY CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 121 GERMANY CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 122 GERMANY HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 123 GERMANY HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 124 GERMANY TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 125 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 126 GERMANY POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 127 GERMANY SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 128 GERMANY OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 129 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 130 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 131 GERMANY HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 132 GERMANY CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 133 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 134 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 135 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 136 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 137 U.K. CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 U.K. CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 139 U.K. HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 140 U.K. HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 141 U.K. TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 142 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 143 U.K. POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 144 U.K. SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 145 U.K. OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 146 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 147 U.K. WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 148 U.K. HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 149 U.K. CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 150 U.K. WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 151 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 152 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 153 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 154 FRANCE CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 155 FRANCE CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 156 FRANCE HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 157 FRANCE HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 158 FRANCE TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 159 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 160 FRANCE POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 161 FRANCE SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 162 FRANCE OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 163 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 164 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 165 FRANCE HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 166 FRANCE CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 167 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 168 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 169 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 170 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 171 ASIA-PACIFIC CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 172 ASIA-PACIFIC CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 173 ASIA-PACIFIC HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 174 ASIA-PACIFIC HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 175 ASIA-PACIFIC TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 176 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 177 ASIA-PACIFIC POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 178 ASIA-PACIFIC SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 179 ASIA-PACIFIC OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 180 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 181 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 182 ASIA-PACIFIC HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 183 ASIA-PACIFIC CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 184 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 185 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 186 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 187 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 188 CHINA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 189 CHINA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 190 CHINA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 191 CHINA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 192 CHINA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 193 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 194 CHINA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 195 CHINA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 196 CHINA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 197 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 198 CHINA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 199 CHINA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 200 CHINA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 201 CHINA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 202 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 203 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 204 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 205 JAPAN CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 206 JAPAN CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 207 JAPAN HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 208 JAPAN HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 209 JAPAN TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 210 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 211 JAPAN POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 212 JAPAN SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 213 JAPAN OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 214 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 215 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 216 JAPAN HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 217 JAPAN CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 218 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 219 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 220 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 221 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)

TABLE 222 AUSTRALIA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 223 AUSTRALIA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 AUSTRALIA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 225 AUSTRALIA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 226 AUSTRALIA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 227 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)

TABLE 228 AUSTRALIA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 229 AUSTRALIA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 230 AUSTRALIA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 231 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 232 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 233 AUSTRALIA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 234 AUSTRALIA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 235 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

图片列表

FIGURE 1 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE WOMEN SEXUAL WELLNESS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 6 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 7 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 8 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 9 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: DBMR MARKET POSITION GRID

FIGURE 10 EUROPE WOMEN SEXUAL WELLNESS MARKET: DBMR MARKET POSITION GRID

FIGURE 11 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: DBMR MARKET POSITION GRID

FIGURE 12 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 13 EUROPE WOMEN SEXUAL WELLNESS MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 14 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 15 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: VENDOR SHARE ANALYSIS

FIGURE 16 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: SEGMENTATION

FIGURE 17 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES ARE EXPECTED TO DRIVE THE NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET IN THE FORECAST PERIOD

FIGURE 18 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES ARE EXPECTED TO DRIVE THE EUROPE WOMEN SEXUAL WELLNESS MARKET IN THE FORECAST PERIOD

FIGURE 19 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES ARE EXPECTED TO DRIVE THE ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET IN THE FORECAST PERIOD

FIGURE 20 THE HUMAN PAPILLOMAVIRUS (HPV) TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET IN 2023 & 2030

FIGURE 21 THE HUMAN PAPILLOMAVIRUS (HPV) TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE WOMEN SEXUAL WELLNESS MARKET IN 2023 & 2030

FIGURE 22 THE HUMAN PAPILLOMAVIRUS (HPV) TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET IN 2023 & 2030

FIGURE 23 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NA, EUROPE AND APAC WOMEN SEXUAL WELLNESS MARKET

FIGURE 24 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2022

FIGURE 25 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 26 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 27 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 28 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2022

FIGURE 29 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 30 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 31 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 32 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2022

FIGURE 33 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 34 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 35 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 36 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2022

FIGURE 37 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2023-2030 (USD MILLION)

FIGURE 38 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, CAGR (2023-2030)

FIGURE 39 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, LIFELINE CURVE

FIGURE 40 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2022

FIGURE 41 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2023-2030 (USD MILLION)

FIGURE 42 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, CAGR (2023-2030)

FIGURE 43 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, LIFELINE CURVE

FIGURE 44 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2022

FIGURE 45 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2023-2030 (USD MILLION)

FIGURE 46 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, CAGR (2023-2030)

FIGURE 47 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, LIFELINE CURVE

FIGURE 48 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2022

FIGURE 49 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 50 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 51 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 52 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2022

FIGURE 53 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 54 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 55 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 56 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2022

FIGURE 57 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 58 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 59 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 60 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2022

FIGURE 61 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 62 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 63 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, LIFELINE CURVE

FIGURE 64 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2022

FIGURE 65 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 66 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 67 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, LIFELINE CURVE

FIGURE 68 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2022

FIGURE 69 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 70 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 71 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, LIFELINE CURVE

FIGURE 72 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 73 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 74 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 75 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 76 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 77 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 78 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 79 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 80 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 81 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 82 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 83 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 84 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: SNAPSHOT (2022)

FIGURE 85 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022)

FIGURE 86 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 87 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 88 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: TEST TYPE (2023-2030)

FIGURE 89 EUROPE WOMEN SEXUAL WELLNESS MARKET: SNAPSHOT (2022)

FIGURE 90 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022)

FIGURE 91 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 92 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 93 EUROPE WOMEN SEXUAL WELLNESS MARKET: TEST TYPE (2023-2030)

FIGURE 94 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: SNAPSHOT (2022)

FIGURE 95 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022)

FIGURE 96 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 97 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 98 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: TEST TYPE (2023-2030)

FIGURE 99 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: COMPANY SHARE 2022 (%)

FIGURE 100 EUROPE WOMEN SEXUAL WELLNESS MARKET: COMPANY SHARE 2022 (%)

FIGURE 101 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: COMPANY SHARE 2022 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

North America, Europe, and Asia-Pacific Women Sexual Wellness Market is known to be worth USD 2,834.39 million by 2030.
The North America, Europe, and Asia-Pacific Women Sexual Wellness Market growth rate is 9.5% by 2030.
Test type, test location, technology, end user, and distribution channel are the factors on which the North America, Europe and Asia-Pacific Women Sexual Wellness Market research is based.
The major companies in the North America, Europe and Asia-Pacific Women Sexual Wellness market are Trinity Biotech, BIOMÉRIEUX, Accuquik Test Kits., JOYSBIO (Tianjin) Biotechnology Co., Ltd, Arbor Vita, Randox Laboratories Ltd., Chembio Diagnostics, Inc., Cepheid., ELITech Group, Abbott, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Sekisui Diagnostics (A Part of SEKISUI Chemical Co. Ltd.), Quidel Corporation, BD., OraSure Technologies, Hologic, Inc., Biomed Diagnostics, and a DCN DX Brand among others.
Growing incidences of sexually transmitted diseases are the growth drivers of the North America, Europe and Asia-Pacific Women Sexual Wellness Market.